November 10, 2011 — The results of an analysis of 149 EVEREST II high surgical risk patients with significant mitral regurgitation (MR) of functional etiology were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2011. Michael Argenizano, M.D., chief of adult cardiac surgery for New York-Presbyterian Hospital/Columbia University Medical Center made the presentation.
